These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23614860)

  • 1. [Aspirin and cancer: evidence of a prophylactic effect].
    Algra AM; Nortier JW
    Ned Tijdschr Geneeskd; 2013; 157(17):A5189. PubMed ID: 23614860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force.
    Chubak J; Whitlock EP; Williams SB; Kamineni A; Burda BU; Buist DS; Anderson ML
    Ann Intern Med; 2016 Jun; 164(12):814-25. PubMed ID: 27064482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
    Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
    Patrono C
    Eur Heart J; 2013 Nov; 34(44):3403-11. PubMed ID: 23771843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin in the prevention of cancer.
    Wald NJ; Morris JK; Law MR
    Lancet; 2011 May; 377(9778):1649; author reply 1651-2. PubMed ID: 21571138
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
    Algra AM; Rothwell PM
    Lancet Oncol; 2012 May; 13(5):518-27. PubMed ID: 22440112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
    van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
    Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis.
    Stegeman I; Bossuyt PM; Yu T; Boyd C; Puhan MA
    PLoS One; 2015; 10(7):e0127194. PubMed ID: 26151751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer.
    Squires H; Tappenden P; Cooper K; Carroll C; Logan R; Hind D
    Clin Ther; 2011 Sep; 33(9):1289-305. PubMed ID: 21840057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for primary prevention: do potential benefits outweigh the risks?
    Shakib S
    Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
    Hassan C; Rex DK; Cooper GS; Zullo A; Launois R; Benamouzig R
    Gut; 2012 Aug; 61(8):1172-9. PubMed ID: 21997545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice.
    Battistoni A; Mastromarino V; Volpe M
    Clin Cardiol; 2015 Jun; 38(6):387-94. PubMed ID: 25873555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of aspirin in primary prevention: is it time for a new approach?
    Brotons C; Benamouzig R; Filipiak KJ; Limmroth V; Borghi C
    Am J Cardiovasc Drugs; 2015 Apr; 15(2):113-33. PubMed ID: 25502483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
    Bibbins-Domingo K;
    Ann Intern Med; 2016 Jun; 164(12):836-45. PubMed ID: 27064677
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.